Jonathan David Tward

Dr. Jonathan David Tward

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
JMJames L. Mohler
James L. Mohler
EAEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
AAAndrew J. Armstrong
Andrew J. Armstrong
ADAnthony V. D’amico
Anthony V. D’amico
BDBrian J. Davis
Brian J. Davis
DFDeborah A. Freedman-Cass
Deborah A. Freedman-Cass
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

1 February 2008 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ABAaron. P. Brown
Aaron. P. Brown
JCJergin Chen
Jergin Chen
YHYing J. Hitchcock
Ying J. Hitchcock
ASAniko Szabo
Aniko Szabo
DSDennis C. Shrieve
Dennis C. Shrieve
JTJonathan David Tward
Jonathan David Tward
Background: The 10-yr survival rate of patients with differentiated thyroid cancer exceeds 90%. These patients may be at elevated risk for secondary cancers. Methods: The risk of nonthyroid second primary malignancies after differentiated thyroid cancer was determined in 30,278 patients diagnosed between 1973 and 2002 from centers participating in the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. Median follow-up was 103 months (range, 2–359 months). Risk was further assessed for the addition of radioisotope therapy, gender, latency to development of secondary cancer, and age at thyroid cancer diagnosis. Results: There were 2158 patients who developed a total of 2338 nonthyroid second primary malignancies, significantly more than that expected in the general population [observed/expected (O/E) = 1.09; 95% confidence interval (CI), 1.05–1.14; P < 0.05; absolute excess risk per 10,000 person-years (AER) = 6.39]. A significantly greater risk of second primary malignancies over that expected in the general population was for patients treated with radioisotopes (O/E = 1.20; 95% CI, 1.07–1.33; AER = 11.8) as well as for unirradiated patients (O/E = 1.05; 95% CI, 1.00–1.10; AER = 3.53). However, the increased risk was greater for the irradiated vs. the unirradiated cohort (relative risk = 1.16; 95% CI, 1.05–1.27; P < 0.05). Gender did not affect risk. The greatest risk of second primary cancers occurred within 5 yr of diagnosis and was elevated for younger patients. Conclusions: The overall risk of second primary malignancies is increased for thyroid cancer survivors and varies by radioisotope therapy, latency, and age at diagnosis.

8 May 2014 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
JMJames L. Mohler
James L. Mohler
PKPhilip W. Kantoff
Philip W. Kantoff
AAAndrew J. Armstrong
Andrew J. Armstrong
RBRobert R. Bahnson
Robert R. Bahnson
MCMichael Cohen
Michael Cohen
MHMaria Ho
Maria Ho
Prostate cancer has surpassed lung cancer as the most common cancer in men in the United States. The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer based on clinical evidence and expert consensus. NCCN Panel guidance on treatment decisions for patients with localized disease is represented in this version. Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations. The full version of these guidelines, including treatment of patients with advanced disease, can be found online at the NCCN website. Prostate cancer has surpassed lung cancer as the most common cancer in men in the United States. The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer based on clinical evidence and expert consensus. NCCN Panel guidance on treatment decisions for patients with localized disease is represented in this version. Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations. The full version of these guidelines, including treatment of patients with advanced disease, can be found online at the NCCN website.

5 October 2017 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
PSPhilippe E. Spiess
Philippe E. Spiess
NANeeraj Agarwal
Neeraj Agarwal
RBRick Bangs
Rick Bangs
SBStephen A. Boorjian
Stephen A. Boorjian
MBMark K. Buyyounouski
Mark K. Buyyounouski
LGLisa A. Gurski
Lisa A. Gurski
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non–muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.

6 September 2012 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
JMJames L. Mohler
James L. Mohler
AAAndrew J. Armstrong
Andrew J. Armstrong
RBRobert R. Bahnson
Robert R. Bahnson
BBBarry Boston
Barry Boston
JBJ. Erik Busby
J. Erik Busby
DSDorothy A. Shead
Dorothy A. Shead
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.

22 September 2006 in Cancer
Verified
Journal Article
Open access
PDF file
OMO. Kenneth Macdonald
O. Kenneth Macdonald
CLChristopher Lee
Christopher Lee
JTJonathan David Tward
Jonathan David Tward
CCCraig D. Chappel
Craig D. Chappel
DGDavid K. Gaffney
David K. Gaffney
BACKGROUND.: Malignant phyllodes tumor is a rare and potentially aggressive breast neoplasm. Little information is available regarding the optimal management of these lesions and rarer still are data regarding survival. The current study used a large population database to determine prognostic factors that predict cause‐specific survival (CSS).METHODS.: Data were obtained from the Surveillance, Epidemiology, and End Results Program (SEER) for the years 1983–2002. Women receiving resection for primary nonmetastatic malignant phyllodes tumor of the breast were included (n= 821). Analyses of patient, pathologic, and treatment characteristics were performed using univariate and multivariate Cox regression analyses for the CSS endpoint.RESULTS.: With a median follow‐up of 5.7 years, CSS was 91%, 89%, and 89%, at 5, 10, and 15 years, respectively. Mastectomy was performed in 428 women (52%) and wide excision or lumpectomy in 393 (48%). Women undergoing mastectomy were significantly older (P= .004) and had larger tumors (P= .009). Wide excision was associated with equivalent or improved CSS relative to mastectomy on univariate and multivariate analyses. Older age predicted for cause‐specific mortality on multivariate analysis. Adjuvant radiotherapy (RT) predicted for worse CSS when implemented compared with surgery alone.CONCLUSIONS.: Mastectomy was not found to provide a benefit in CSS compared with wide excision in malignant phyllodes tumor of the breast. Women undergoing wide excision had at the minimum similar cancer‐specific mortality compared with those who received mastectomy. The role of adjuvant RT is uncertain and requires further investigation. Cancer 2006. © 2006 American Cancer Society.